AU2023241731A1 - Respiratory stimulant nasal formulations - Google Patents

Respiratory stimulant nasal formulations Download PDF

Info

Publication number
AU2023241731A1
AU2023241731A1 AU2023241731A AU2023241731A AU2023241731A1 AU 2023241731 A1 AU2023241731 A1 AU 2023241731A1 AU 2023241731 A AU2023241731 A AU 2023241731A AU 2023241731 A AU2023241731 A AU 2023241731A AU 2023241731 A1 AU2023241731 A1 AU 2023241731A1
Authority
AU
Australia
Prior art keywords
substituted
nasal formulation
formulation
compound
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023241731A
Other languages
English (en)
Inventor
Frank Diana
Joseph V. PERGOLIZZI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enalare Therapeutics Inc
Original Assignee
Enalare Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enalare Therapeutics Inc filed Critical Enalare Therapeutics Inc
Publication of AU2023241731A1 publication Critical patent/AU2023241731A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2023241731A 2022-04-01 2023-03-31 Respiratory stimulant nasal formulations Pending AU2023241731A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263326578P 2022-04-01 2022-04-01
US63/326,578 2022-04-01
PCT/US2023/017126 WO2023192602A2 (en) 2022-04-01 2023-03-31 Respiratory stimulant nasal formulations

Publications (1)

Publication Number Publication Date
AU2023241731A1 true AU2023241731A1 (en) 2024-10-31

Family

ID=88195037

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023241731A Pending AU2023241731A1 (en) 2022-04-01 2023-03-31 Respiratory stimulant nasal formulations

Country Status (10)

Country Link
US (1) US20230310440A1 (https=)
EP (1) EP4504206A4 (https=)
JP (1) JP2025511227A (https=)
KR (1) KR20240167901A (https=)
CN (1) CN119630402A (https=)
AU (1) AU2023241731A1 (https=)
CA (1) CA3247210A1 (https=)
MX (1) MX2024012104A (https=)
TW (1) TW202345837A (https=)
WO (1) WO2023192602A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025511227A (ja) * 2022-04-01 2025-04-15 エナラーレ セラピューティクス インコーポレイテッド 呼吸器刺激性経鼻製剤
US20230414624A1 (en) * 2022-06-24 2023-12-28 Enalare Therapeutics Inc. Methods of treating neurological ventilatory insufficiency
KR102882277B1 (ko) 2023-11-22 2025-11-06 헤일러코리아 주식회사 구분된 공간을 구비하는 교체형 카트리지 및 이를 포함하는 네블라이징 디바이스
KR102908992B1 (ko) 2023-11-22 2026-01-14 박세진 네블라이징 디바이스용 교체형 카트리지

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US20050053659A1 (en) * 2003-09-10 2005-03-10 Pace Gary W. Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness
US20120295911A1 (en) * 2010-11-29 2012-11-22 Galleon Pharmaceuticals, Inc. Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
AU2011336764B2 (en) * 2010-11-29 2017-02-23 Galleon Pharmaceuticals, Inc. Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
WO2012138797A1 (en) * 2011-04-05 2012-10-11 Amira Pharmaceuticals, Inc. 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders
SG11201407964YA (en) * 2012-05-29 2014-12-30 Galleon Pharmaceuticals Inc Novel compounds and compositions for treatment of breathing control disorders or diseases
US11903951B2 (en) * 2016-06-03 2024-02-20 M et P Pharma AG Nasal pharmaceutical compositions with a porous excipient
WO2019182745A1 (en) * 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
CA3141612A1 (en) * 2019-05-22 2020-11-26 Enalare Therapeutics Inc. Methods and pharmaceutical compositions to treat drug overdose
CA3236586A1 (en) * 2021-11-02 2023-05-11 Joseph Pergolizzi Methods of treating respiratory depression modulated by a non-opioid agent
JP2025511227A (ja) * 2022-04-01 2025-04-15 エナラーレ セラピューティクス インコーポレイテッド 呼吸器刺激性経鼻製剤

Also Published As

Publication number Publication date
WO2023192602A3 (en) 2024-01-18
CA3247210A1 (en) 2023-10-05
JP2025511227A (ja) 2025-04-15
WO2023192602A2 (en) 2023-10-05
US20230310440A1 (en) 2023-10-05
TW202345837A (zh) 2023-12-01
EP4504206A2 (en) 2025-02-12
KR20240167901A (ko) 2024-11-28
MX2024012104A (es) 2025-01-09
EP4504206A4 (en) 2026-03-25
CN119630402A (zh) 2025-03-14

Similar Documents

Publication Publication Date Title
US20230310440A1 (en) Respiratory stimulant nasal formulations
US20250114370A1 (en) Methods and compositions for treating drug overdose
US20250032496A1 (en) Methods of treating respiratory depression modulated by a non-opioid agent
US12150461B2 (en) Nicotinamide adenine dinucleotide (NAD) compositions, methods of manufacturing thereof, and methods of use thereof
US20230210857A1 (en) Respiratory stimulant parenteral formulations
US20240238303A1 (en) Large-conductance potassium channel modulators, compositions thereof, methods of manufacturing thereof, and methods of use thereof
US20230414624A1 (en) Methods of treating neurological ventilatory insufficiency
CN118829433A (zh) 呼吸刺激剂肠胃外制剂
TW202529771A (zh) 用於治療藥物過量的方法及組合物
CA3217969A1 (en) Nicotinamide adenine dinucleotide (nad) compositions, methods of manufacturing thereof, and methods of use thereof